Hormonal
Bariatric/metabolic surgery induces rapid type 2 diabetes remission through weight-independent mechanisms, primarily involving altered gut hormone secretion (GLP-1, PYY), bile acid metabolism, and intestinal glucose disposal, occurring before significant weight loss.
For individuals with T2DM, bariatric surgery offers a potent, rapid improvement in blood sugar control that is driven by hormonal and metabolic changes in the gut, not just weight loss. This makes it a highly effective treatment for eligible candidates, particularly those who have not achieved remission through lifestyle changes alone. However, it is not suitable for everyone, especially those with long-standing diabetes and depleted insulin production.
Improvement in glucose homeostasis after RYGB, VSG, and BPD typically begins within days of surgery, before significant weight loss occurs. Thus, total body weight loss per se is unlikely to play a significant role in mediating early glycemic improvements.
Why this rating
Based on a comprehensive review of seminal human studies, animal models, and replicated clinical outcomes.
Source
Mechanisms of Diabetes Improvement Following Bariatric/Metabolic Surgery
Rachel L. Batterham et al. · Diabetes Care · 2016
DOI 10.2337/dc16-0145
More from this paper
- The exaggerated postprandial secretion of GLP-1 and PYY following Roux-en-Y gastric bypass (RYGB) and Vertical Sleeve Gastrectomy (VSG) contributes to improved glucose tolerance and insulin sensitivity, although its necessity is debated.Good
- Bile acid metabolism and the gut microbiome are critical mediators of glycemic improvement after bariatric surgery, acting through FXR and TGR5 receptors to influence glucose production and utilization.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →